Confronting a Silent Killer

Coronary Artery Disease (CAD) claims the lives of hundreds of thousands of Americans each year, costing the U.S. healthcare system billions. Current diagnostic methods, like the Framingham Risk Score (FRS), rely on patient history and offer limited accuracy, leaving many at risk of undetected heart disease.

Bio-MedPoint: A Breakthrough in Precision

Bio-MedPoint's disruptive diagnostic technology is changing the game. Our proprietary algorithms analyze blood serum samples to identify patients with CAD with an astounding 94% accuracy – more than double the accuracy of the FRS.

Key Advantages:

• Unmatched Accuracy: Identify CAD with confidence, empowering physicians to make informed treatment decisions.

• Early Detection: Detect the disease even in its early stages, potentially preventing heart attacks and saving lives.

• Personalized Insights: Reveal varying degrees of disease severity, allowing for tailored treatment plans.

• Leverages Existing Infrastructure: Our technology seamlessly integrates with existing laboratory machines, minimizing disruption and costs.

• Minimal Sample Requirement: Requires only a small blood serum sample, ensuring patient comfort and convenience.

• Significant Profit Potential: With estimated costs of $7 per blood sample, the opportunity for substantial margins is clear.

Empowering Physicians, Protecting Patients

Bio-MedPoint empowers physicians to proactively identify and manage CAD, even in patients who may not exhibit traditional risk factors. By providing a more accurate and comprehensive picture of a patient's cardiovascular health, we're helping to prevent heart attacks, reduce healthcare costs, and ultimately save lives.

A Future of Precision Medicine

Bio-MedPoint represents a significant advancement in the field of cardiovascular diagnostics. Our technology has the potential to transform the way we approach heart disease, offering a more precise, personalized, and proactive approach to patient care.